Local injection of infliximab into calcinosis lesions in patients with juvenile dermatomyositis (JDM): a clinical trial
Authors' conclusion
The results suggest that the direct administration of infliximab into the calcinosis lesions of patients with JDM could be a safe and effective treatment approach.
Study context
- Population
- Patients with JDM and calcinosis lesions
- Participants
- 5 patients
- Comparison
- Local injection of infliximab into calcinosis lesions; lesion size before vs after treatment
- Infliximabn = 5
- Outcome
- Lesion dimensions (length and width), monitored weekly; radiographic assessment before intervention and after final injection
- Follow-up
- Week 16
Methodological detailsGeneralized Estimating Equation (GEE) analysis
- GEE analysis
Main finding
As reported in the abstract
Lesion size per visit (GEE)
Mean reduction in lesion length per visit
2.66%
Mean reduction in lesion width per visit
3.32%
Further findings
Radiographic lesion length, initial visit vs last visit
Range Initial visit 6.00-25.50 mm · Last visit 0-23.00 mm
Radiographic lesion width, initial visit vs last visit
Range Initial visit 2.00-16.00 mm · Last visit 0-13.00 mm
Safety
- No specific side effects related to the treatment were reported
Original publication
Local injection of infliximab into calcinosis lesions in patients with juvenile dermatomyositis (JDM): a clinical trial. Pediatr Rheumatol Online J. Published 2 January 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →